Why ICU Medical, Inc.’s (ICUI) Stock Is Up 12.16%
As of Friday, August 07, ICU Medical, Inc.’s ICUI share price has surged by 12.16%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company’s customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Commentary & Analysis
What You Need to Know About ICU Medical, Inc.'s Q3 Earnings
ICU Medical, Inc.'s fiscal Q3 earnings report was released on Thursday, August 06. Let's dive in to see if (ICUI) missed or beat analyst's expectations.Michael Rose
Is ICU Medical, Inc. (ICUI) Overvalued?
We dive into why ICU Medical, Inc. (ICUI) could be considered overvalued on 2026-07-30, based on AAII’s Value Score and Grade.Tudor Pop
Which Is a Better Investment, Butterfly Network, Inc. or ICU Medical, Inc. Stock?
Learn more about whether Butterfly Network, Inc. or ICU Medical, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Why ICU Medical, Inc.’s (ICUI) Stock Is Up 5.88%
As of Thursday, June 04, ICU Medical, Inc.’s ICUI share price has surged by 5.88%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ICUI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,084.1 | $367.8 | 65% |
|
| Shares Out (Mil) | 25.0 | 40.8 | 34% |
|
| Institutional Ownership | 98.3% | 82.8% | 78% |
|
| Float (Mil) | 24.6 | 35.5 | 32% |
|
| Beta | 0.76 | 0.85 | 45% |
|
| Avg Daily Volume (000s) | 244 | 310 | 45% |
|
| Price Change (52-week) |
23.9% | 65.6% | 71% |
|
| Growth | ICUI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 11.9% | 11.8% | 65% |
|
| Net Income (5yr) | (61.9%) | (5.7%) | 5% |
|
| EPS (5yr) | (62.5%) | 10.2% | 2 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.9%) | (15.5%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 8 | 8 | |
| Current EPS | $2.147 | $8.753 | $9.646 | |
| Month Ago EPS | $2.147 | $8.753 | $9.646 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 2 | |
| Three Months Ago EPS | $2.080 | $8.158 | $9.303 | |
| Year/Year Chg | 182.5% | 29,077% | 34,450% | |
| Financials | ICUI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,160 | $119 | 61% |
|
| Net Income (TTM) (Mil) | $30 | ($9) | 51% |
|
| EPS (TTM) | $1.214 | ($0.400) | 63% |
|
| Operating Cash Flow (TTM) (Mil) | $236 | ($3) | 61% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $1 | 38% |
|
| Long-Term Debt (Q1) (Mil) | $1,253 | $23 | 68% |
|
| Enterprise Value (Q1) (Mil) | $4,808 | $376 | 62% |
|
| Valuation | ICUI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.90 | 2.72 | 50% |
|
| P/E | 135.6 | 25.7 | 96% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | ICUI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 38.3% | 58.5% | 47% |
|
| Net Margin | 1.4% | (6.9%) | 36% |
|
| ROA | 0.7% | (12.3%) | 43% |
|
| ROE | 1.4% | (11.1%) | 37% |
|
| Liabilities to Assets | 45.8% | 46.6% | 37% |
|
| F-Score | 6 | 4 | 67% |
|
Passing Stock Screens
As of 9/23/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.2% |
| +/- S&P 500: | +5.7 |
